Yongwei Su, Jenna L Carter, Xinyu Li, Yu Fukuda, Ashley Gray, John Lynch, Holly Edwards, Jun Ma, Patrick Schreiner, Lisa Polin, Juiwanna Kushner, Sijana H Dzinic, Steven A Buck, Shondra M Pruett-Miller, Katie Hege Hurrish, Camenzind Robinson, Xinan Qiao, Shuang Liu, Shuangshuang Wu, Guan Wang, Jing Li, Joshua E Allen, Varun V Prabhu, Aaron D Schimmer, Dhananjay Joshi, Shiva Kalhor-Monfared, Iain D G Watson, Richard Marcellus, Methvin B Isaac, Rima Al-Awar, Jeffrey W Taub, Hai Lin, John D Schuetz, Yubin Ge
Eradication of acute myeloid leukemia (AML) is therapeutically challenging; many patients succumb to AML despite initially responding to conventional treatments. Here, we showed that the imipridone ONC213 elicits potent antileukemia activity in a subset of AML cell lines and primary patient samples, particularly in leukemia stem cells, while producing negligible toxicity in normal hematopoietic cells. ONC213 suppressed mitochondrial respiration and elevated alpha-ketoglutarate by suppressing alpha-ketoglutarate dehydrogenase (α-KGDH) activity...
January 24, 2024: Cancer Research